Amgen 2009 Annual Report Download - page 69

Download and view the complete annual report

Please find page 69 of the 2009 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 180

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180

Item 2. PROPERTIES
The following table summarizes our significant properties and their primary functions as of December 31,
2009. For additional information regarding manufacturing initiatives see “Item 1. Business — Manufacturing,
Distribution and Raw Materials.”
Location
Owned
Leased
Aranesp ®
Neulasta ®
NEUPOGEN ®
Epoetin alfa
Enbrel ®
Other Products
denosumab
Other
United States:
Thousand Oaks, California ............................................................... 36
-5
22
61
-1
-1
6-
31
61
-6
-3
19 -
-5
-1
-2
-2
81
1-
1-
-4
6F
F
B
Fremont, California .......................................................................... B
F
B
San Francisco, California .................................................................
Boulder, Colorado ............................................................................ BB
Longmont, Colorado ........................................................................ BB
Washington, D.C. .............................................................................
Louisville, Kentucky ........................................................................
Cambridge, Massachusetts ...............................................................
Foxboro, Massachusetts ...................................................................
West Greenwich, Rhode Island ........................................................ BB
Bothell, Washington .........................................................................
Seattle, Washington ..........................................................................
Other U.S. cities ...............................................................................
Outside United States:
Canada ..............................................................................................
Puerto Rico ....................................................................................... B
F
B
F
B
FF FFF
B
F
Australia ...........................................................................................
Japan .................................................................................................
Netherlands ...................................................................................... F1 F1
Ireland ..............................................................................................
Switzerland .......................................................................................
United Kingdom ...............................................................................
Other countries .................................................................................
B - Bulk manufacturing
F - Formulation, Fill and Finish
F1 - Finish onl
y
Number of
spaces or
buildings:
Other Functions
Commercial:
Administrative
Research and/or Development
Sales and Marketing
Warehouse
Distribution Center
Clinical:
Manufacturing
B
F1 F1 F1 F1
-4
-35
57